New York, NYCIK 19581254 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
45 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Gilead Sciences Inc | 289.3K | $35.51M | 6.3% | +289.3K | New |
| 2 | Bristol-Myers Squibb Co | 647.9K | $34.95M | 6.2% | +647.9K | New |
| 3 | Boston Scientific Corp | 360.4K | $34.37M | 6.1% | +97.5K | Added |
| 4 | Bridgebio Oncology Therapeut |
| 410.7K |
| $31.41M |
| 5.6% |
| +410.7K |
| New |
| 5 | Eli Lilly & Co | 25.9K | $27.86M | 4.9% | −31.5K | Reduced |
| 6 | Dianthus Therapeutics Inc | 653.6K | $26.93M | 4.8% | −14.0K | Reduced |
| 7 | Ascendis Pharma A/S | 119.3K | $25.43M | 4.5% | −25.7K | Reduced |
| 8 | Syndax Pharmaceuticals Inc | 1.20M | $25.14M | 4.4% | −417.9K | Reduced |
| 9 | Johnson & Johnson | 120.8K | $25.01M | 4.4% | +120.8K | New |
| 10 | Regeneron Pharmaceuticals | 29.8K | $23.00M | 4.1% | −5.5K | Reduced |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio